BiovaxID Demonstrates High Overall Survival in Mantle Cell Lymphoma

Biovest has announced that the National Cancer Institute (NCI) has presented outcomes at this past weekend's American Society of Clinical Oncology annual meeting from a Phase II BiovaxID lymphoma vaccine clinical trial.

The results of the clinical trial showed that vaccination with BiovaxID following rituximab combination chemotherapy induced nearly universal T-cell immune responses that strongly correlated with overall survival (OS) and time-to-next treatment benefits in patients with the aggressive B-cell non-Hodgkin's lymphoma, mantle cell lymphoma (MCL).

BiovaxID improved survival time

"We found that among MCL patients treated with a hybridoma-based idiotype vaccine, patients who had T-cells that produced GM-CSF when exposed to tumor antigen had a significantly longer survival and delayed time to next treatment compared to patients who did not have GM-CSF producing T-cells," Said principal investigator Wyndham H. Wilson, M.D., Ph.D., Chief of the Lymphoma Therapeutics Section at NCI and the of the MCL study, "Interestingly, studies have shown that GM-CSF producing T-cells are important for promoting autoimmunity, which is what we hope an antitumor vaccine will do. In the latter case, the autoimmunity is against a tumor antigen and not a normal cell."

The study (involving 24 participants), with 122 months of median potential follow-up, showed a median overall survival of 104 months, a time that exceeded reported historic OS rates for 'low-risk' MIPI patients and substantially exceeding reported historic overall survival rates for 'high-risk' and 'intermediate-risk' MIPI patients.

In sum, the study shows a statistically-significant association between OS and specific vaccine-induced anti-tumor GM-CSF cytokine (T-cell) responses.

Sattva S. Neelapu, M.D., Associate Professor at the Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, co-investigator of this Phase II study and an investigator on another trial, noted that "These results complement the body of data supporting the safety and efficacy of BiovaxID."

Source: MarketWatch

mantle cell lymphoma

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...